BRPI0517327A - derivados de pirimidina e seu uso como moduladores ppar-alfa - Google Patents

derivados de pirimidina e seu uso como moduladores ppar-alfa

Info

Publication number
BRPI0517327A
BRPI0517327A BRPI0517327-2A BRPI0517327A BRPI0517327A BR PI0517327 A BRPI0517327 A BR PI0517327A BR PI0517327 A BRPI0517327 A BR PI0517327A BR PI0517327 A BRPI0517327 A BR PI0517327A
Authority
BR
Brazil
Prior art keywords
pyrimidine derivatives
ppar
treatment
alpha modulators
production
Prior art date
Application number
BRPI0517327-2A
Other languages
English (en)
Inventor
Elke Dittrich-Wengenroth
Lars Baerfacker
Axel Kretschmer
Claudia Hirth-Dietrich
Peter Ellinghaus
Martin Raabe
Hilmar Bischoff
Christian Pilger
Ulrich Rosentreter
Stephan Bartel
Klemens Lustig
Armin Kern
Dieter Lang
Marcus Bauser
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of BRPI0517327A publication Critical patent/BRPI0517327A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

DERIVADOS DE PIRIMIDINA E SEU USO COMO MODULADORES PPAR-ALFA. A presente invenção refere-se aos novos derivados de pirimidina da fórmula geral (I), processos para a sua produção, seu uso para o tratamento e/ou profilaxia de doenças, bem como seu uso para a produção de medicamentos para o tratamento e/ou profilaxia de doenças, preferivelmente para o tratamento e/ou prevenção de doenças cardiovasculares, especialmente de dislipidemias, arteriosclerose, insuficiência cardíaca, trombose e da síndrome metabólica.
BRPI0517327-2A 2004-09-25 2005-09-10 derivados de pirimidina e seu uso como moduladores ppar-alfa BRPI0517327A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004046623A DE102004046623A1 (de) 2004-09-25 2004-09-25 Neue Pyrimidin-Derivate und ihre Verwendung
PCT/EP2005/009734 WO2006032384A1 (de) 2004-09-25 2005-09-10 Neue pyrimidin-derivate und ihre verwendung als ppar-alpha-modulatoren

Publications (1)

Publication Number Publication Date
BRPI0517327A true BRPI0517327A (pt) 2008-10-07

Family

ID=35063041

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517327-2A BRPI0517327A (pt) 2004-09-25 2005-09-10 derivados de pirimidina e seu uso como moduladores ppar-alfa

Country Status (22)

Country Link
US (1) US20080261990A1 (pt)
EP (1) EP1797045A1 (pt)
JP (1) JP2008514559A (pt)
KR (1) KR20070055621A (pt)
CN (1) CN101065364A (pt)
AR (1) AR051295A1 (pt)
AU (1) AU2005287589A1 (pt)
BR (1) BRPI0517327A (pt)
CA (1) CA2582492A1 (pt)
DE (1) DE102004046623A1 (pt)
EC (1) ECSP077340A (pt)
GT (1) GT200500266A (pt)
IL (1) IL182136A0 (pt)
MA (1) MA28882B1 (pt)
MX (1) MX2007003428A (pt)
NO (1) NO20072051L (pt)
PE (1) PE20060657A1 (pt)
RU (1) RU2007115215A (pt)
SV (1) SV2007002235A (pt)
TW (1) TW200628451A (pt)
UY (1) UY29127A1 (pt)
WO (1) WO2006032384A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0809655B8 (pt) * 2007-04-13 2021-05-25 Millennium Pharm Inc uso de um composto e um agente terapêutico,composição farmacêutica,e,kit
KR100813387B1 (ko) * 2007-06-26 2008-03-12 신명곤 부형제 첨가없이 인삼농축액으로 유동성 및 저장성이우수한 인삼농축액환 제조 방법
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CA2809958A1 (en) 2010-08-31 2012-03-08 Snu R & Db Foundation Use of the fetal reprogramming of a ppar ? agonist
EA201891154A1 (ru) 2011-10-28 2019-02-28 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
SG11201401816SA (en) 2011-10-28 2014-05-29 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
CN103130732A (zh) * 2011-11-22 2013-06-05 上海博康精细化工有限公司 3,5-二甲基-4-氯甲基异噁唑的制备方法
KR20160002773A (ko) 2013-03-15 2016-01-08 루메나 파마수티컬즈, 인코포레이티드 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
MX2015013196A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett.
WO2017190050A1 (en) * 2016-04-28 2017-11-02 Cornell University Inhibitors of soluble adenylyl cyclase
BR112021015809A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Resposta dependente de genótipo e dose a um asbti em pacientes com deficiência de bomba de exportação de sal biliar
CN115598267B (zh) * 2022-12-13 2023-05-09 山东省食品药品检验研究院 一种格列齐特中潜在遗传毒性杂质的分析方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU72201A (sh) * 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
GB0214254D0 (en) * 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
WO2006032384A1 (de) 2006-03-30
EP1797045A1 (de) 2007-06-20
DE102004046623A1 (de) 2006-03-30
AR051295A1 (es) 2007-01-03
ECSP077340A (es) 2007-04-26
UY29127A1 (es) 2006-04-28
RU2007115215A (ru) 2008-11-10
MA28882B1 (fr) 2007-09-03
SV2007002235A (es) 2007-03-20
CA2582492A1 (en) 2006-03-30
KR20070055621A (ko) 2007-05-30
NO20072051L (no) 2007-06-07
TW200628451A (en) 2006-08-16
PE20060657A1 (es) 2006-08-12
JP2008514559A (ja) 2008-05-08
AU2005287589A1 (en) 2006-03-30
CN101065364A (zh) 2007-10-31
US20080261990A1 (en) 2008-10-23
GT200500266A (es) 2006-05-11
IL182136A0 (en) 2007-07-24
MX2007003428A (es) 2008-03-13

Similar Documents

Publication Publication Date Title
BRPI0517327A (pt) derivados de pirimidina e seu uso como moduladores ppar-alfa
ECSP077357A (es) Procedimiento para la preparación de 4-{4-[cloro-3-(trifluorometil) fenil] amino}carbonil)amino]fenoxi}n-metilpiridina-2-carboxamida
BRPI0514833A (pt) fenilaminotiazóis substituìdos e seu uso
UY30578A1 (es) Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones
PE20050255A1 (es) Nuevas cianotiazolidas y procedimiento para su preparacion como medicamentos
BRPI0507309A (pt) derivados de ácido 7-fenilamino-4quinolon-3-carboxìlico, processos para produção e seu uso como medicamento
ATE516285T1 (de) Dihydropyridinonderivate
DOP2006000062A (es) Derivados de acido pirimidincarboxilico y su uso
BRPI0510411A (pt) derivados de dióxido de oxazol-benzoisotiazol, processos para a sua fabricação e seu uso
BR0312549A (pt) Derivados de indolin-fenilsulfonamida
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
BRPI0515485A (pt) compostos heteroarila como betamiméticos para o tratamento de doenças das vias respiratórias
UY31310A1 (es) Ácidos 6-fenilnicotínicos sustituidos y su uso
ATE530526T1 (de) Lactam-substituierte dicarbonsäuren und ihre verwendung
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
CR11272A (es) Enzimas de aciltranferasa de lecitina-colesterol, modificadas
ECSP088569A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y uso de los mismos para el tratamiento de enfermedades cardiovasculares
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
UY29264A1 (es) Tiazolidinonas metasustituidas, su preparación y su uso como medicamento
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
UY30582A1 (es) Derivados de acido 2-fenoxinicotinico y su uso
BR112014018226A8 (pt) Derivados de pirimidooxazocina como inibidores de mtor
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
BRPI0418404A (pt) derivados de benzazepina tricìclicos como inibidores da sìntese do esqualeno para o tratamento de doenças cardiovasculares
MX2007010841A (es) 8-pirrolidinobenzimidazoles biciclicos sustituidos, un metodo para su produccion y su uso como medicamentos.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]